{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:20:36Z","timestamp":1772749236011,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,2]],"date-time":"2015-07-02T00:00:00Z","timestamp":1435795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010511","name":"Clinical and Translational Science Institute, University of California, San Francisco","doi-asserted-by":"publisher","award":["UL1 TR000004"],"award-info":[{"award-number":["UL1 TR000004"]}],"id":[{"id":"10.13039\/100010511","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.clinthera.2015.06.004","type":"journal-article","created":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T17:15:26Z","timestamp":1438449326000},"page":"2130-2134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Enzyme Replacement Therapies and Immunogenicity in Lysosomal Storage Diseases: Is There a Pattern?"],"prefix":"10.1016","volume":"37","author":[{"given":"Paul","family":"Harmatz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.06.004_bib1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1083\/jcb.201208152","article-title":"The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction","volume":"199","author":"Platt","year":"2012","journal-title":"J Cell Biol"},{"key":"10.1016\/j.clinthera.2015.06.004_bib2","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/B978-0-444-59565-2.00042-3","article-title":"Mucopolysaccharidoses and mucolipidoses","volume":"113","author":"Wraith","year":"2013","journal-title":"Handb Clin Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2015.06.004_bib3","first-page":"88","article-title":"Fabry disease","volume":"12","author":"Thomas","year":"2013","journal-title":"Pediatr Endocrinol Rev"},{"key":"10.1016\/j.clinthera.2015.06.004_bib4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-1-4684-7735-1_18","article-title":"The enzymic defects in Morquio and Maroteaux-Lamy syndrome","volume":"68","author":"Dorfman","year":"1976","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.clinthera.2015.06.004_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1042\/bj2030335","article-title":"Impaired degradation of keratan sulphate by Morquio A fibroblasts","volume":"203","author":"Gl\u00f6ssl","year":"1982","journal-title":"Biochem J"},{"key":"10.1016\/j.clinthera.2015.06.004_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10545-012-9459-0","article-title":"Clinical overview and treatment options for nonskeletal manifestations of mucopolysaccharidosis type IV A","volume":"36","author":"Hendriksz","year":"2013","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.clinthera.2015.06.004_bib7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1542\/peds.2006-2184","article-title":"Management guidelines for mucopolysaccharidosis VI","volume":"120","author":"Giugliani","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2015.06.004_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-9-32","article-title":"Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey","volume":"9","author":"Hendriksz","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2015.06.004_bib9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.01.021","article-title":"The Morquio A Clinical Assessment Program: baselines results illustrating progressive, multisystemic clinical impairments in Morquio A subjects","volume":"109","author":"Harmatz","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2015.06.004_bib10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ymgme.2014.08.012","article-title":"Multi-domain impact of elosulfase alfa in Morquio A syndrome in the pivotal phase III trial","volume":"114","author":"Hendriksz","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2015.06.004_bib11","unstructured":"VIMIZIM\u00ae US Prescribing Information, BioMarin Pharmaceutical Inc., Novato, CA, 2014. www.vimizim.com."},{"key":"10.1016\/j.clinthera.2015.06.004_bib12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","article-title":"Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study","volume":"37","author":"Hendriksz","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.clinthera.2015.06.004_bib13","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.clinthera.2014.11.005","article-title":"Immunogenicity of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome: results from MOR-004, a phase III trial","volume":"37","author":"Schweighardt","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2015.06.004_bib14","article-title":"A multicenter, open-label, extension study to evaluate the long-term efficacy and safety of BMN 110 in patients with mucopolysaccharidosis IVA (MPS IVA, Morquio A Syndrome)","author":"Hendriksz","year":"2013","journal-title":"ICIEM 12th International Congress of Inborn Errors of Metabolism"},{"key":"10.1016\/j.clinthera.2015.06.004_bib15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10545-007-0529-7","article-title":"International Morquio A Registry: clinical manifestation and natural course of Morquio A disease","volume":"30","author":"Monta\u00f1o","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.clinthera.2015.06.004_bib16","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","article-title":"Immunogenicity to therapeutic proteins: Impact on PK\/PD and efficacy","volume":"14","author":"Chirmule","year":"2012","journal-title":"AAPS J"},{"key":"10.1016\/j.clinthera.2015.06.004_bib17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.clinthera.2015.06.004_bib18","doi-asserted-by":"crossref","first-page":"e67052","DOI":"10.1371\/journal.pone.0067052","article-title":"Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: a step towards improving the efficacy of ERT","volume":"8","author":"Banugaria","year":"2013","journal-title":"PLoS One"},{"issue":"suppl 2","key":"10.1016\/j.clinthera.2015.06.004_bib19","doi-asserted-by":"crossref","first-page":"P18","DOI":"10.1186\/1471-2474-14-S2-P18","article-title":"Antibody formation to enzyme therapy in classic infantile Pompe disease: implications of patient age","volume":"14","author":"Van Gelder","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.clinthera.2015.06.004_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2015.06.004_bib21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"De Vries","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.clinthera.2015.06.004_bib22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ymgme.2011.08.003","article-title":"Atypical immunologic response in a patient with CRIM-negative Pompe disease","volume":"104","author":"Abbott","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2015.06.004_bib23","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.4161\/hv.21405","article-title":"Teaching tolerance: new approaches to enzyme replacement therapy for Pompe disease","volume":"8","author":"Cousens","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.clinthera.2015.06.004_bib24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","article-title":"Anti-\u03b1-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry","volume":"105","author":"Wilcox","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2015.06.004_bib25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ymgme.2013.08.002","article-title":"The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase","volume":"110","author":"Barbier","year":"2013","journal-title":"Mol Gen Metab"},{"key":"10.1016\/j.clinthera.2015.06.004_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajmg.c.31319","article-title":"Predicting cross reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience","volume":"160","author":"Bali","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.clinthera.2015.06.004_bib27","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/humu.20257","article-title":"Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A)","volume":"26","author":"Tomatsu","year":"2005","journal-title":"Human Mutat"},{"key":"10.1016\/j.clinthera.2015.06.004_bib28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ymgme.2011.08.029","article-title":"Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI","volume":"104","author":"Furujo","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2015.06.004_bib29","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1399-0004.2009.01324.x","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study","volume":"77","author":"McGill","year":"2010","journal-title":"Clin Genet"},{"key":"10.1016\/j.clinthera.2015.06.004_bib30","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s40262-014-0173-y","article-title":"Pharmacokinetic and pharmacodynamics evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome","volume":"53","author":"Qi","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2015.06.004_bib31","first-page":"11","article-title":"Enzyme replacement therapy with laronidase (Aldurazyme(\u00ae)) for treating mucopolysaccharidosis type I","author":"Jameson","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2015.06.004_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1750-1172-8-51","article-title":"Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase","volume":"8","author":"Brands","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2015.06.004_bib33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"Benichou","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2015.06.004_bib34","doi-asserted-by":"crossref","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2015.06.004_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","article-title":"Fabry disease, enzyme replacement therapy and the significance of antibody responses","volume":"35","author":"Deegan","year":"2012","journal-title":"J Inherit Metab Dis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815008589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815008589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T19:46:06Z","timestamp":1668627966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815008589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0149291815008589"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.06.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzyme Replacement Therapies and Immunogenicity in Lysosomal Storage Diseases: Is There a Pattern?","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}